Patient Participation: Current Knowledge and Applicability to Patient Safety — Mayo Clinic Proceedings

Ovarian metastases from breast cancer

"Ovarian disease (cancer) was diagnosed at a median of 5 years after breast cancer. Seventy-five percent of patients were asymptomatic, and advanced-stage pelvic extent or extra-abdominal metastases were observed in 41.5% of patients. The median survival was 3 years..."

Safety Considerations and Potential Interactions of Vitamins: Should Vitamins Be Considered Drugs?

"...A, E, D can cause serious adverse events."

The Optimal Debulking after Neoadjuvant Chemotherapy in Ovarian Cancer: Proposal Based on Interval Look During Upfront Surgery Setting Treatment -- Onda et al. 40 (1): 36 -- Japanese Journal of Clinical Oncology

Under-treatment of cancer pain

Identifying novel autoantibody signatures in ovarian cancer

CONCLUSIONS: Protein microarrays are suitable for autoantibody discovery in ovarian cancer but the signatures are of low frequency.

MEMO TO THE MEDIA: Assessing Lead Time of Selected Ovarian Cancer Biomarkers JNCI

Assessing Lead Time of Selected Ovarian Cancer Biomarkers

full free access EDITORIAL: Designing Early Detection Programs for Ovarian Cancer -- JNCI

"...Despite the discovery that CA125 and other serum markers increase before the clinical onset of ovarian cancer, it has proven surprisingly difficult to devise a successful screening program for asymptomatic women with ovarian cancer.....For now, we do not have a proven biomarker, panel of biomarkers, or overall screening program that works well. The current report, with its sobering implications, brings us closer to understanding the crucial elements in designing any effective early detection program for ovarian cancer...."

free full access: Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- JNCI

Note: small study, did not include family history of colorectal cancer (Lynch Syndrome); clear cell ovarian subtype

THE RESEARCH ARTICLE: 
Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study -- Anderson et al., 10.1093/jnci/djp438 -- JNCI Journal of the National Cancer Institute